Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still cancer-free years later in a small early-stage trial, researchers reported in Nature.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their tumors,